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Abstract Treatment of congenital diaphragmatic hernia
(CDH) challenges obstetricians, pediatric surgeons, and
neonatologists. Persistent pulmonary hypertension (PPHT)
associated with lung hypoplasia in CDH leads to a high
mortality rate at birth. PPHT is principally due to an
increased muscularization of the arterioles. Management of
CDH has been greatly improved by the introduction of
prenatal surgical intervention with tracheal obstruction
(TO) and by more appropriate postnatal care. TO appears
to accelerate fetal lung growth and to increase the number
of capillary vessels and alveoli. Improvement of postnatal
care over the last years is mainly due to the avoidance of
lung injury by applying low peak inflation pressure during
ventilation. The benefits of other drugs or technical
improvements such as the use of inhaled nitric oxide or
extracorporeal membrane oxygenation (ECMO) are still
being debated and no single strategy is accepted worldwide.
Despite intensive clinical and experimental research, the
treatment of newborn with CDH remains difficult.
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CDH congenital diaphragmatic hernia
PPHT persistent pulmonary hypertension
TO tracheal obstruction
ECMO extracorporeal membrane oxygenation
NO nitric oxide
HFO high-frequency oscillation
PVR pulmonary vascular resistance
US ultrasound
LHR lung–heart-ratio
MRI magnetic resonance imaging
FETO fetal tracheal occlusion
VEGF-A vascular endothelial growth factor-A
PDGF-B platelet-derived growth factor-B
IGF-II insulin-like growth factor-II
MAPK mitogen-activated protein kinase
ET-1 endothelin-1
FETENDO fetal endoscopic surgery
EXIT ex utero intrapartum treatment
iPPROM iatrogenic preterm rupture of the fetal
membrane
PaCO2 arterial pressure of CO2
GC guanylate cyclase
PDE V cGMP-specific phosphodiesterase
TXA2 thromboxane A2
PGI2 prostacyclin
COX cyclooxygenase enzyme
AC adenylate cyclase
cGMP cyclic 3′–5′-guanylosine monophosphate
PKG cGMP dependent proteine kinase
Kca
2+ K+ channels calcium dependant
iGMP inactive 3′–5′-guanylosine monophosphate
YC-1 A benzyl indazole derivative
AadO2 alveolar-arterial oxygen gradient
VI ventilatory index
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MVI modified ventilatory index
PIP peak inspiratory pressure
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FiO2 inspiratory fraction of oxygen
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GER gastroesophageal reflux
Introduction
Congenital diaphragmatic hernia (CDH) combines a muscle
defect between the abdomen and the thoracic cavity with
pulmonary hypoplasia. The muscle defect leads to a
herniation of the abdominal viscera into the thoracic cavity
[12, 44]. It usually stems from the left posterolateral part of
the muscle and is called Bochdalek hernia [55]. The
Morgagni hernia concerns the antero-medial retrosternal
portion of the diaphragm and the esophageal hiatal hernia
arises from a physiological orifice. Riverius was the first to
describe a CDH in 1679, Morgagni described different
types of diaphragmatic hernia in 1761, and in the nineteenth
century Victor Bochdalek described his autopsies of
children with CDH.
CDH occurs in 1/2,500 to 1/5,000 live births. No
specific causal gene defects have been identified in humans
and most cases are sporadic. A few drugs such as
pyridoxine, thalidomide, quinine, and antiepileptic drugs
have been implicated in the occurrence of CDH. However,
its true incidence is probably higher because some fetuses
with severe CDH die in utero and are spontaneously
aborted. Eighty-four percent of CDH are left-sided, 14%
right-sided, and 2% bilateral [58, 104]. CDH is often
associated with cardiac, gastrointestinal, genitourinary,
skeletal or neural anomalies and with trisomies [48, 58].
The incidence of associated anomalies in infants born with
a CDH ranges from 10% to 40% [27]. In about 30% of
cases, these malformations appear as skeletal defects such
as limb reduction or costovertebral defects [97]. Cardiac
malformations such as hypoplasia of the aortic arch,
tetralogy of Fallot, transposition of the great vessels or aortic
coarctation occur in about 25% of cases [96]. Congenital
tracheal stenosis, tracheal bronchus or other tracheal
malformations can also be found in association with CDH
[74]. Neural tube defects seem to be the most common
findings in infants with CDH who died in utero [96].
CDH alone has a mortality rate of 20% and the degree of
associated pulmonary hypoplasia and the severity of pulmo-
nary hypertension remain the major determinant of survival
[89]. When the associated anomalies are severe, the
mortality rate can be as high as 90% [58]. Stege et al.
[90] showed that the two factors which clearly influence
postnatal mortality are the timing of the termination of
gestation and the presence of additional anomalies. They
showed that the survival rate of infants diagnosed with
CDH has not improved in the past 10 years despite new
therapies, and that half of the cases had not been detected
by antenatal scanning, leading to the birth of infants with a
life-threatening condition in an unprepared obstetric unit.
They also noted that CDH had remained undiagnosed in
some infants who had died immediately after birth [90].
Therefore, the overall mortality of children with a CDH is
difficult to determine.
Long-term compression of fetal lungs by the herniation
of the viscera into the thoracic cavity results in pulmonary
underdevelopment and lung hypoplasia [3, 36, 55]. This
was confirmed in both ipsilateral and contralateral pulmo-
nary specimens by an analysis of lung volumes and weights
during autopsies of humans and of animal models [76].
Structural alterations in CDH lungs are a decrease of the total
arteriolar cross-sectional area and a significant adventitial
and medial wall thickening in pulmonary arteries of all sizes,
with abnormal muscularization of the small pre-acinar and
intra-acinar arterioles, leading to a persistent pulmonary
hypertension (PPHT) which causes the death of babies
before or after birth [18, 67]. The probability of survival in
children born with CDH is therefore determined mainly by
the severity of lung hypoplasia and the presence of PPHT
causing abnormal pulmonary compliance, refractory respi-
ratory failure at birth, hypoxemia, right to left extrapulmo-
nary shunting of blood, progressive acidosis (Fig. 1) and
heart failure [51, 68].
Even fetuses which survive up to delivery have
significant lung hypoplasia and impaired lung function
which lead to long-term morbidity. Since the 1980s, there
have been many advances in the care of neonates, in
particular the introduction of drugs such as the surfactant,
and later the discovery by Furchgott and Zawadzki [32] of
nitric oxide (NO), which can reduce PPHT in most
pathologies. Other advances were the use of high-frequency
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Fig. 1 Physiopathology of the persistent pulmonary hypertension
(PPHT) in CDH
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oscillation (HFO) and extracorporeal membrane oxygena-
tion (ECMO). Although all these advances have proved
efficient in most diseases related to PPHT, treatment of
CDH remains difficult and challenging as no single
treatment has yet proved to be very efficient [100]. Surgery
“in utero”, with the insertion of a temporary tracheal
occlusion (TO) to improve lung growth and lung capacity,
is a new approach in the treatment of children with CDH
but its indication in cases of fetuses with severe lung
hypoplasia is still debated.
Anomalies of pulmonary vascularity [117], such as
hyperplasia of the smooth muscle cells play a decisive role
in maintaining a high pulmonary vascular resistance
(PVR), pulmonary vascular compliance and therefore
blood flow [34]. The smaller arteries, those with an
external diameter of less than 200 µm, are predominantly
responsible for PVR [99]. To be more precise, pulmonary
vascular abnormalities in CDH consist in a decreased
number of pulmonary arteries per unit of lung volume and
in the peripheral muscularization of small arteries, with
medial and adventitial thickening [85, 117]. Increased
adventitial and medial thickness of the pulmonary arterial
wall is the most striking structural changes which have
been reported in patients with CDH complicated by PPHT
[34]. The presence of abnormally thick-walled pulmonary
arteries in newborn with CDH suggests that their intra-
pulmonary arteries may become excessively muscularized
during fetal life and unable to adapt normally at birth. In
fetuses, studies of blood flow with a 3-D Doppler showed
decreased vascularity, decreased pulmonary blood flow,
and decreased pulmonary blood flow per volume of blood
vessels [80].
Management
There is to this day no consensus on the treatment of
babies with PPHT. Studies on the treatment of these
children have to be interpreted carefully for different
reasons: firstly, comparisons of the degree of herniation
are difficult, and the criteria applied to determine whether
a CDH is moderate or severe are not always the same
and may bias the appraisal of patients and affect the
decision on the mode and timing of the treatment;
secondly, no criteria for the selection of a particular
treatment have been validated in large series, and the
choice of treatment depends largely on the strong belief
of the team-leader; and thirdly, the survival rate is higher
in large centers, where a great number of children are
born or transferred every year, than in smaller centers
where these cases are few and far between [47].
The evaluation of a fetus suspected of presenting CDH
includes a prenatal high-resolution ultrasound (US) exam-
ination to confirm the diagnosis. Between 40% and 60% of
infants with CDH are diagnosed prenatally [33]. Normally,
the first sign evidenced by US is the presence of fluid-filled
loops of bowel in the thorax. The small bowel and the
stomach are both involved in 90% of cases. A bad
prognosis can be presaged before birth on the basis of
different signs and measurements provided by US: an early
diagnosis at 24 weeks of gestation with a large muscular
defect, a dilated intrathoracic stomach, a herniated left lobe
of the liver and the presence of a polyhydramnios are
predictive of severe pulmonary hypertension at birth and of
a poor outcome [94]. Subsequent US examinations are
performed to assess the contents of the hernia, evaluate any
associated malformations and measure the lung–heart ratio
(LHR). It is important to know the position of the liver
because the prognosis for a baby with a herniated liver is
not good. A US–Doppler examination can be done to check
the position of the umbilical vein and of the hepatic vessels.
Various indexes have been proposed to evaluate the
prognosis after a US examination. In 2000, Suda [94]
showed that the most significant prognostic factor was the
modified McGoon index, which is the diameter of the
proximal pulmonary artery indexed to the descending aorta.
An index of 1.3 or less predicts mortality with a sensitivity
of 85% and a specificity of 100%.
Magnetic resonance imaging (MRI) realized prenatally
can be of importance to resolve a doubt about the position
of the liver, to evaluate the volume of the lungs or to
distinguish a CDH from other malformations such as a
cystic adenomatoid malformation, pulmonary sequestration,
bronchogenic cyst, enteric cysts or mediastinal teratoma.
This technique is an excellent mode of imaging when an
exquisite anatomical detail has to be discussed precisely.
Karyotyping is also mandatory as CDH is frequently
associated with chromosomal anomalies.
Several choices can be envisioned and proposed to the
parents of a child with a CDH diagnosed prenatally and a
bad prognosis: interrupt the pregnancy (before 24 weeks),
let the pregnancy follow its course up to delivery, or
consider prenatal surgery and TO. As CDH has a
significant mortality rate, there is a hope that an interven-
tion in utero may improve the outcome for the child.
Prenatal management
A multidisciplinary team includes at least neonatalogists,
obstetricians, pediatric surgeons, geneticists, and cardiolo-
gists. Fetal surgery is normally shared by pediatric surgeons
and obstetricians but the management of each case and the
decision to perform surgery must be the result of a
multidisciplinary discussion which takes into account the
context of the malformation, the various signs indicative of
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its gravity, the gestational age at diagnosis, and the family’s
history and likelihood to consent to the procedure [14].
In 1990, Harrison et al. in San Francisco were the
first to operate in utero on children with CDH [38]. This
new surgical approach encountered difficulties, and its
results were not always completely successful. There was a
high rate of preterm deliveries due to infection and
difficulties in maintaining tocolysis. The reduction of a
liver herniated into the thorax proved difficult and
provoked an obstruction of the umbilical blood flow and
the death of the fetus [39].
Tremendous advances were made following the obser-
vation that the prevention of a normal efflux of intraluminal
lung liquid has a positive influence on lung growth by
stimulating the development of pulmonary parenchyma
[114]. This finding led to the concept that occluding the
trachea before birth (Fetal Tracheal Occlusion or FETO)
could enhance lung growth and improve the outcome after
birth [21, 30, 40, 41].
Animals with CDH treated by tracheal occlusion
developed lungs whose appearance and function were
normal, and their rate of survival was significantly
improved in comparison to control animals [23]. In sheep
and rats with a nitrofen-induced CDH [54, 63], tracheal
occlusion results in lung growth, and morphometric studies
show a decrease in the thickening of the small pulmonary
arteries [50, 54].
Attempts were made to explain the mechanism of lung
adaptation after FETO by searching for the presence of
such molecules as vascular endothelial growth factor-A
(VEGF-A), platelet-derived growth factor-B (PDGF-B),
insulin-like growth factor-II (IGF-II), mitogen-activated
protein kinase (MAPK) or endothelin-1 (ET-1) [11, 37,
111].
Indication and measurements
Fetal surgery is a treatment which is available only in the
few centers which receive a sufficient number of cases [47].
While counseling on the possibility of fetal surgery and the
organization of the delivery is normally provided by a team
of neonatologists, gynecologists, geneticians, and pediatric
surgeons, fetal surgery itself relies also on the expertise of
other teams such as radiologists and on the availability of
special instrumentation, and its complexity precludes its
widespread application and limits its execution to a few
highly specialized fetal treatment centers.
Although a variety of indexes have been suggested, there
are as yet no real markers to determine the gravity of the
pulmonary hypertension which will be found at birth. The
capability of identifying high-risk fetuses in the prenatal
period is crucial in order to select those fetuses which will
benefit from prenatal high-risk interventions. Actually, two
criteria are taken into consideration in the selection of high-
risk fetuses:
– The position of the liver. Fetuses whose liver is
partially herniated into the thoracic cavity have a 50%
chance of survival [19, 80].
– The ratio between lung and head (Fig. 2), called LHR
[59, 60, 84]. Group A: A LHR lower than 0.6 points to
a very poor outcome for the fetus, with extreme lung
hypoplasia and a mortality rate of almost 100%. Group
B: a ratio between 0.6 and 1 gives the fetus which has a
severe lung hypoplasia a predictive survival rate of 15
to 60%. FETO is normally proposed for these babies.
Group C: a ratio in the range of 1.0 to 1.6 gives the
child a 66% chance of survival and a predictive
survival rate of more than 83% [60, 84]. However,
even for these babies, the indication of FETO is under
discussion as the beneficial effect of FETO has not yet
been proved. In a prospective series in 1997, Lipshutz
[60] showed that no fetus having a LHR of less than 1
survived to a postnatal age of 60 days, and that only
children with a LHR greater than 1.4 could survive.
But it has also been demonstrated that LHR is not a
predictive factor in fetuses with a left CDH and a
normal position of the liver [84].
On the basis of these two criteria, the FETO procedure,
with the PLUG being inserted between 26 and 28 weeks of
gestation, and the UNPLUG performed at 34 weeks of
gestation, is proposed for fetuses showing (1) a LHR of less
Fig. 2 Example of lung-to-head ratio (LHR) measured during
ultrasonography. H heart; arrow pulmonary diameter. A LHR lower
than 0.6 points to a very poor outcome for the fetus, a ratio between
0.6 and 1 gives the fetus a better predictive survival rate of 15 to 60%
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than 1, (2) a herniation of a large portion of the liver
including part of the left lobe, (3) a normal genetic
karyotype, (4) no associated abnormalities and (5) a
singleton pregnancy at 25 weeks of gestation. One must
also make sure that the anesthesia and surgery will not put
the mother at risk. The timing and duration of the occlusion
are the subjects of discussion and research as they are
crucial to the beneficial effect of the procedure, i.e.,
increased pulmonary stretch and accelerated growth of
airways and pulmonary vessels.
Surgery
After routine preoperative laboratory studies and a physical
examination, an ultrasound examination is carried out to
check the viability of the fetus. Indomethacin is given in the
morning to provide uterine relaxation. An epidural block is
placed to allay the pain of the mother and the fetus.
Compression stockings are used as a precaution against
thromboembolic risks. Anesthesia is realized with isoflur-
ane inhalation to ensure uterine relaxation. The patient is
draped for surgery.
Two important advances in this prenatal surgery have
been developed: the first advance is the development of the
technique which allows the procedure to be performed
fetoscopically, whereby a balloon is inserted percutaneously
through a 3.3 mm incision to create the endoluminal
tracheal occlusion at 26–28 weeks of gestation. Previously,
surgery in utero entailed a hysterotomy: the maternal
abdomen was opened by a low transverse laparotomy, a
hysterotomy was performed under ultrasound control. A
pulse oximetry device was applied to the hand and the
throat was exposed for a midline neck dissection in order to
isolate the trachea. The trachea was occluded by two
hemoclips facing each other. Closure was then executed
layer by layer. Continuous patient-controlled epidural
analgesia was provided for the relief of maternal postoper-
ative pain. Tocolysis was ensured by intravenous doses of
magnesium sulfate and indomethacin and continued to the
end of the pregnancy. Bed rest was normally prescribed for
the mother, who was monitored for signs and symptoms of
preterm labor. Follow-up ultrasound examinations were
performed to measure lung parenchyma and check on the
expected gradual increase in lung volume. But the rate of
survival of the fetuses was low and the morbidity of
survivors not acceptable [39]. Then, in 2000, it was
reported that fetoscopic endoluminal tracheal occlusions
had been performed on lamb fetuses [77] with endoscopic
instruments. This type of surgery, called FETENDO for
“fetal endoscopic surgery”, was later also performed on
human fetuses [21, 40, 41].
The second advance was the improvement in the
material used for tracheal occlusions. The placement below
the vocal cords of a water impermeable and expandable
polymeric foam in a gelatin capsule, introduced into the
trachea by means of a fetoscope with a detachable balloon
occlusion system, appears to be well tolerated by the fetus
and to stimulate excellent lung growth without causing
tracheal damage [20]. The fetoscope has a diameter of
1.2 mm, in a sheath whose diameter measures 3 mm. This
method represents a marked advance on the fetoscopic fetal
occlusion with clips, which can give rise to numerous
surgical complications [41].
The restoration of airway potency by removal of the
balloon can be realized prior to birth at 34 weeks of
gestation, or by “Ex utero Intrapartum Treatment (EXIT)”
during delivery. The first method avoids the drawback of a
long-term tracheal occlusion which provokes the differen-
tiation of type II pneumocytes into type I pneumocytes with
surfactant deficiency. The procedure is performed prior to
birth, at 34 weeks of gestation, either by fetal tracheoscopy,
by ultrasound-guided puncture of the balloon using a
fetoscope, or by deflation of an expandable balloon [20].
It is carried out under locoregional anesthesia or epidural
anesthesia, with prophylactic tocolysis for the mother and
fentanyl and pancuronium for the fetus [8]. The risk
entailed by this procedure is the “iatrogenic preterm rupture
of the fetal membrane” or iPPROM [8, 20].
The second method, EXIT, is a procedure which
allows the retrieval of the balloon by tracheoscopy
during birth. It can only be performed in institutions
which have the appropriate equipment [8]. Labor is
induced shortly before term and a laparotomy and a
hysterotomy are performed under deep anesthesia to effect
uterine relaxation and a good uterine perfusion. The neck of
the baby is quickly exposed to allow the removal of the
balloon or of the tracheal clips and to do a bronchoscopy.
The baby is then intubated and given surfactant. Once it is
stabilized in the neonatal intensive care unit, CDH repair is
performed.
There is no proof that the outcome is more favorable for
children who had a PLUG installed in utero, and a
randomized trial was terminated early after showing that
they fared no better than children who had not had a PLUG
but had been delivered in specialized centers [19, 20].
Nevertheless, further attempts were made on fetuses with a
very low prognosis following precise measurements in
utero [41]. In 2006, Deprest [19] reported a 75% neonatal
survival rate, with 90% patch repair in 66% of operated
children, and a 58% neonatal survival rate in 24 consecu-
tive cases of CDH where the mean duration of tracheal
occlusion had been 42 days. Although preliminary results
of FETO surgery are encouraging, there is as yet no
statistical proof that fetal surgery offers better results than
postnatal management in terms of survival and long-term
morbidity. A randomized study in at least one center should
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therefore be carried out before FETO surgery becomes
widespread.
Postnatal treatment
At birth, babies with CDH will have a flat abdomen, bowel
sounds in the chest, cardiac sounds shifted laterally, and
breathing difficulties. All efforts should be made to stabilize
the cardiopulmonary system during resuscitation with a
minimum of iatrogenic injuries. When the CDH is severe,
the babies are normally intubated to relieve respiratory
distress, and a gastric tube is inserted to decompress the
stomach. Ventilation by mask is contraindicated as it may
cause a distention of the stomach situated in the thoracic
cavity. Arterial and venous access should be acquired
through the umbilical vessels in order to obtain blood gas
samples and to monitor central venous pressure. Adequate
oxygen delivery must be given, with proper temperature
regulation and glucose homeostasis. The children must be
sedated but muscle paralysis is not encouraged because of
its untoward consequences on ventilatory mechanics.
Systemic hypotension must be reversed with fluid admin-
istration. A chest radiography will usually show gas-filled
loops of bowel in the chest along with a shift of the heart to
the other side of the defect (Fig. 3). When the CDH is mild,
symptoms may not be immediately manifest and can appear
only after several months [25].
Advances in neonatal reanimation have greatly improved
the outcome of babies born with CDH. The introduction of
different types of ventilation, the use of NO and the use of
extracorporeal membrane oxygenation (ECMO) are respon-
sible for this improvement. Nevertheless, the benefits of
these various techniques and drugs are still being debated
and there is as yet no general agreement on the application
of one or the other. Even if these techniques taken
individually have not proved truly beneficial to babies born
with a CDH, their conjunction, or at times their alternance,
is beneficial. But more long-term follow-up data on the
results of these treatments is needed to assess the mortality
and morbidity of children born with a severe CDH. An
additional problem is the fact that a truly valid comparison
of treatment results can only be made if the children treated
present an equal degree of gravity of their CDH.
Conventional ventilation
The optimal mode of ventilation for children with CDH at
birth is not defined. Conventional ventilation is based on
“gentle” ventilation to avoid any barotrauma which could
add another pulmonary problem to the existing pulmonary
hypertension. The principle of “gentle” ventilation is based
on controlling the peak inflation pressure (18 to 22 cmH2O)
by limiting the pressure of ventilation while tolerating an
oxygen saturation of 85% and a rise of the arterial pressure
of CO2 (PaCO2; permissive hypercapnia), and stimulating
spontaneous ventilation [1, 61, 83, 116]. Boix-Ochoa was
the first to report that differences in pre- and postductal pH
and PaCO2 could be used to differentiate survivors and non
survivors, thereby demonstrating the influence of the pH
and the PaCO2 on pulmonary vascular tone and ductal
shunting [7]. Transporters of gas such as perfluorocarbons
can be used as a medium for liquid ventilation. Due to their
weak solubility in lipids, they reduce the surface tension of
the alveoli and allow a lower pressure of ventilation.
Perfluorocarbons can also be used for the local administra-
tion of anesthetics and vasodilators [115].
Barotrauma is an additional and leading cause of
morbidity and mortality in children with CDH [110].
Studies have demonstrated that increased mortality in
children with CDH was due to a high ventilatory rate and
a high inspiratory pressure [87]. The mechanisms of
ventilator-induced pulmonary damage involve a structural
disruption due to lung overdistension and shear–stress
forces generated by the repetitive opening and collapse of
the atelectatic regions of the lung. These mechanisms
induce a capillary leak in the endothelium and epithelium,
a rupture of the basement membrane, a leakage of fluid in
the alvealor spaces, a general inflammatory response and an
impairment of the secretion of surfactant [110].
High-frequency oscillation (HFO)
HFO was introduced in the 1980s in an attempt to
ameliorate gas exchange in the lung by avoiding the high
inspiratory pressure produced by conventional ventilation
Fig. 3 At birth, a chest radiography will usually show gas-filled loops
of bowel in the chest (left side on this radiograph) along with a shift
of the heart to the other side of the defect (right side on this
radiograph)
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and keeping a mean airway pressure of about 15 cmH2O
and an amplitude of less than 45 mmHg [6, 57]. HFO can
used as the first choice of ventilation for babies born with
CDH or when conventional ventilatory strategies fail. There
is actually no proof that HFO is better than conventional
ventilation [5] but the low-tidal-volume regimen induced by
HFO may be less deleterious to the lungs than a high-tidal-
volume ventilation [9]. The choice of different modes of
ventilation depends largely on the convictions of different
teams, who quite try alternate strategies of ventilation when
pulmonary hypertension due to CDH does not respond to a
first treatment. The teams who chose HFO as a ventilatory
strategy reported good results even in children with a bad
prognosis [22].
Surfactant
Suen et al. [95] have shown that lung immaturity in babies
with CDH can lead to a deficiency of disaturated
phosphatidylcholine and a deficiency of surfactant [113].
These findings have not been confirmed by other groups
[119]. Most studies on the lack of surfactant were carried
out mainly on animal models such as rats, where the
production of surfactant seems to be ameliorated by the
administration of vitamin A [101, 103].
Even though the use of exogenous surfactant in children
with CDH has not been studied in a controlled clinical trial,
it constitutes a standard treatment in the fight against PPHT
in children with CDH, especially in conjunction with other
treatments. It has been proved in animal models (rats and
lambs) that lungs with CDH are deficient in surfactant [35].
There is little data on the deficiency of surfactant in human
lungs at birth [62, 66, 70]. Recent research has shown that
there was no difference in the amount of surfactant in
infants with or without CDH [28] and that surfactant
treatment during ECMO brought no improvement [13]. But
despite the absence of supportive data and of controlled
clinical trials to test the effect of exogenous surfactant, it is
commonly used in most centers for babies born with CDH
[70, 109]. In summary, not only is there no proof that the
administration of exogenous surfactant is beneficial, but it
may even not be without risk. Complications of the
administration of surfactant, such as a drop in arterial
pressure, increased cerebral blood flow velocity or non
responders, are infrequent [43].
Calcium channel blockers
Although calcium channel blockers are the first treatment
for pulmonary hypertension, there are no reports of the use
of these drugs in children with PPHT associated with CDH.
Nevertheless, these drugs are often used in combination
with others, as drug combinations have proved more
effective than a single drug alone, especially when a
disease is resistant to treatment.
NO
The discovery and the use of NO in recent years is one of
the major advances in the understanding of vascular
regulation [32]. NO is a potent vasodilator produced by
the endothelial cells of vessels, including pulmonary
vessels. It improves oxygenation by decreasing PVR
reducing pulmonary shunts. In human fetal lungs, the NO
pathway is involved in angiogenesis, lung development,
and vasorelaxation [53]. NO is known to modulate
neutrophils and platelet adhesion, vascular smooth muscle
proliferation, and capillary leak by reducing vascular
permeability [79]. NO gives the vessels the ability to self-
regulate contraction and relaxation (Fig. 4).
Inhaled NO is very efficient when treating pulmonary
PPHT and respiratory failure in infants or newborn
suffering from various diseases [10]. But it is not so in
the case of children suffering from pulmonary hypertension
due to CDH, and the presence and activation of the NOS is
still a subject of wide discussion [88, 100]. NO is
nevertheless used against pulmonary hypertension in
CDH, in combination with mechanical ventilation/HFO,
surfactant, and antihypertensive drugs. There has as yet
been no randomized trial focused on the role of NO itself to
assess its benefits and, worse, one publication reports a
poorer outcome in children with CDH treated with NO
[29].
Side effects of NO in high concentration are the
potentialization of lung injury promoting oxidative stress,
the inactivation of the surfactant production, the impairment
of ciliary motility, and the increase in tissue inflammation
and vascular permeability following plasma extravasation
[79]. Inhalation of highly concentrated NO may convert it
into a highly toxic peroxynitrite which may activate
macrophages and impair surfactant production. The lungs
of the newborn seem to be protected against birth-related
oxidative stress by an increase in antioxidant activity [83].
Oxidative stress is responsible for dysregulation of the
vascular tone, platelet aggregation, and increased vascular
permeability. It contributes to apoptosis through changes in
ionic transport, activation of enzymes and changes in the
cystoskeleton [81].
Guanylate cyclase and cGMP-specific phosphodiesterase
Postnatal pulmonary vascular tone is influenced by various
vasoconstrictors or vasodilators. Vasoconstrictors such as
ET-1 or thromboxane A2 (TXA2) increase the vascular
resistance [102], although ET-1 may also play a role in
vasodilation in the newborn [75]. TXA2 and prostacyclin
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(PGI2) are prostaglandins produced by the degradation of
arachidonic acid by the cyclooxygenase enzyme (COX)
[17]. Among vasodilators, NO [10, 53] activates soluble
Guanylate cyclase (GC) found in vascular smooth muscle
and PGI2 activates the smooth-muscle-membrane-bound
enzyme adenylate cyclase (AC) [17], thereby increasing
the level of cyclic 3′–5′-guanylosine monophosphate
(cGMP).
The cGMP dependent proteine kinase (PKG) activates
calcium-dependent K+ channels (Kca
2+) through phosphor-
ylation. The resulting hyperpolarization of the cell mem-
brane inhibits the ion influx through voltage operated Ca2+
channels and causes vasodilation [82]. But cGMP is in turn
rapidly inactivated by phosphodiesterase (PDE V) enzyme
and is transformed into inactive 3′–5′-guanylosine mono-
phosphate (iGMP) which limits the vasodilatory response
to NO [118] (Fig. 4). New management strategies in order
to diminish persistent pulmonary hypertension at birth are
based on the role of agents activating the GC, such as YC-1
(a benzyl indazole derivative) or inhibiting the PDE V, such
as sildenafil [86].
ECMO
The use of ECMO is also controversial, and the choice of
this interventional therapy is based largely on the belief of
individual team leaders. This technique has become a
standard treatment in specialized centers for infants born
with a CDH, even though one large randomized trial of
ECMO reported in the literature reached conclusions which
are not very precise and was unable to show its benefit over
other techniques [107]. As usual, the main problem in
comparing results is the difficulty to guarantee the integrity
of the groups of children with CDH who receive a
particular treatment, as the criteria applied to select these
children are widely divergent [24]. Criteria for the use of
ECMO vary widely from center to center, and the final
decision is often reached only when an infant shows a
clinical deterioration, a deterioration of blood gases, a
mechanical ventilation with a peak inspiratory pressure
higher than 25 mmHg, a compliance measurement less than
0.25 mL/cmH2O/kg and a tidal volume less than 3.5 mL/kg
[92]. Investigators have proposed different formulas based
on blood gas components to predict the outcome of babies
with CDH and to argue about the use of ECMO: the first is
the alveolar-arterial oxygen gradient (AadO2) calculated by
the formula: AadO2=[(713×FiO2)−PaCO2/0.8]−PaO2,
FiO2 being the inspiratory fraction of O2 and PaO2 the
arterial pressure of O2. The second is the ventilatory index
(VI) calculated by the formula: VI=(RR×MAP×PaCO2),
RR being the respiratory rate, MAP the median arterial
pressure with a good prognosis when the index is less than
1000. The third is a modified VI (MVI) calculated by the
formula MVI=(RR×PIP×PaCO2), PIP being the peak
inspiratory pressure, and a result of less than 40 offers a
good prognosis, a result of more than 80 a bad prognosis.
Finally, the most commonly used calculation is the
oxygenation index (OI) calculated by the formula OI=
(MAP×FiO2/PaO2), with initiation of ECMO for an OI of
40 or greater [57, 93]. Both venovenous and venoarterial
techniques have been reported with equally effective results
[56].
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CDH repair
The rule in most centers is to delay surgery until the
pulmonary hypertensive crisis in children born with CDH
has been controlled. This period of adaptation at birth
permits the stabilization of labile hemodynamic and
pulmonary physiology as both lungs are affected by this
pathology [42]. Nevertheless, studies tend to show that the
timing of surgery makes no difference in the outcome of
early and late repair groups [71]. The decision as to the
optimum timing of surgery after birth must be discussed by
a multidisciplinary team and must first and foremost take
into account the stability of the child and its capacity to
tolerate “gentle” ventilation with low peak pressure, a FiO2
lower than 50%, a minimum of inhaled NO, and good
blood gas values [116]. Serial heart ultrasound examina-
tions can help to assess blood flow shunts and pulmonary
hypertension in comparison with systemic pressure. Never-
theless, the repair of a diaphragmatic defect will often
worsen pulmonary compliance by reducing the elasticity of
the chest wall and increasing the intraabdominal pressure.
Surgery usually begins with a subcostal incision giving
access to the entire diaphragm. The spleen, the small
intestine and the large intestine are generally herniated
through the defect. When the herniated viscera have been
reduced, the edges of the diaphragm should be recognized.
This obliges the surgeon to dissect the posterior part of the
diaphragm, which is often quite thin. Ideally, the diaphragm
is closed after the reduction of the viscera with non
absorbable interrupted sutures. Mattress sutures or pledg-
etted sutures can also be used. A laparoscopic approach in
the skilled hands of a surgeon who is used to this particular
surgical method is also possible and depends largely on the
hemodynamic and the pulmonary stability of the child. A
transthoracic approach to repair the defect is also described,
especially for a CDH on the right side, and affords a nice
view for a liver reduction [42].
Primary repair is not always possible. In the presence of
a tension too excessive to permit primary repair, of a very
large defect in a thin diaphragm or even an absent
diaphragm, or of agenesis of the diaphragm, a prosthetic
implant may be needed to close the defect. Technically, this
implant must be attached all around in order to decrease the
risk of recurrence of the hernia, and its attachment to the
lateral part to the ribs and to the medial part of the thoracic
cavity while safeguarding the passage of the esophagus and
the aorta is challenging [69, 93]. There is as yet no optimal
patch material. The current materials are too rigid. This
rigidity creates problems when the patient grows as the
prosthetic implant does not adapt to the growth of the
thoracic cavity, leading to thoracic deformation and
scoliosis [69]. The development of bioengineered materials,
also for other indications than CDH, would be of great
interest. Other technical solutions, such as a reversed
latissimus dorsi muscle flap for the repair of recurrent
CDH, have also been described [98].
Long-term follow-up
Specialized multidisciplinary clinics are emerging in many
centers to provide long-term follow-up for children born
with CDH. These children require the services of expert
pediatricians who are trained in specific areas such as
pulmonary, digestive, or musculoskeletal pathologies.
As children with a large defect and those with PPHT will
often have multiple problems, a long follow-up is manda-
tory. The follow-up data for all children born with CDH
shows that even those for whom recovery during the
neonatal period is relatively easy may still have long-term
problems. These problems can be recurrent herniation,
delayed growth, chronic lung disease, feeding complica-
tions, gastroesophageal reflux, neurological impairment,
deafness, and musculoskeletal deformations [49, 52, 105,
106, 108]. Factors such as parental socioeconomic status
and education may contribute to making a long-term
follow-up more difficult [2, 15].
Pulmonary problems concern obstructive or restrictive
pulmonary function anomalies, or a combination of both.
Persistent pulmonary hypoplasia produces ventilation per-
fusion mismatch and chronic lung disease with obstructive
airway disease [72, 73]. Children who suffer from these
problems may need oxygen support for a long time and are
discharged and sent home with the means to pursue this
therapy. Chronic lung disease is defined as the need for
ventilatory support, chronic bronchodilators, diuretics, or
oxygen supplementation [16]. Bronchospasm, asthma, and
wheezing are frequently reported in the literature [105].
Bronchial hyperreactivity to pharmacological products has
also been reported [106]. A long-term study by Vanamo et
al. [106] of young adults born with CDH or with a
diaphragmatic eventration and treated between 1948 and
1980 showed that 83% of these patients considered
themselves normal, that 12% had asthma and that 4% had
recurrent respiratory tract infections. More recently, based
on 100 consecutive CDH survivors, Muratore [73] showed
that 16% of the patients remained oxygen-dependent for
several months after their discharge and 43% diuretic-
dependent for a maximum of 30 months after their
discharge, and that viral bronchiolitis was strongly preva-
lent in children under 3 years of age. Kamata et al. [49]
showed that morbidity due to recurrent pneumonia was the
most prevalent (39%) among 33 CDH survivors who were
followed for many years. Keller [52] reported in three
patients born with CDH a persistent high pulmonary arterial
pressure and a high PVR, measured by cardiac catheteriza-
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tion between the ages of three months and 12 years.
Recently, Jaillard et al. [45] found after a 2-year follow-up
that chronic lung disease was prevalent in CDH survivors,
with a higher prevalence in children treated with ECMO or
whose hernia had been repaired with a patch. Finally chest
radiography may evidence hyperlucency, hyperinflation,
persistent lung hypoplasia, decreased pulmonary vascular-
ity, persistent lung opacities, mediastinal shift, or abnormal
diaphragmatic profile [2].
Esophagogastric problems may present as esophageal
dysmotility and gastroesophageal reflux (GER) and can
occur in more than 50% of CDH children [26, 91]. Failure
to thrive due to these feeding-related problems is frequent
in this population [73]. The variability in the data reported
in various studies concerning the incidence of GER may
depend on the method of diagnosis, for instance good
clinical investigation, pH monitoring, milk-scan study and
upper gastrointestinal contrast. Despite long discussions
about the etiology of GER in CDH patients, its pathophys-
iology has not yet been elucidated and several anatomical
hypotheses are proposed, such as kinking of the esophagus
at the gastroesophageal junction, shortening of the abdom-
inal esophagus portion, modification of the His angle or
absence of the perihiatal diaphragm [2]. The presence of
GER mandates a close follow-up of these patients, with
appropriate medical treatment and even surgical treatment if
necessary, in order to avoid sudden death, chronic pulmo-
nary disease due to bronchoaspiration and failure to thrive
[15, 104]. Many other factors, such as chronic lung disease,
the use of long-term oxygen, a long period of endotracheal
intubation causing delayed swallowing, or the presence of a
gastrostomy, contribute to eating difficulties and growth
failure. Malrotation is associated with CDH and bowel
obstruction is a well-known complication [64].
Deformities of the chest wall such as pectus excavatum
and deformities of the spine, including scoliosis, are typical
long-term problems which require a long-term follow-up.
More than 40% of CDH survivors will suffer from these
abnormalities [2]. These malformations are due mainly to
the surgical repair with a patch in the case of a large
diaphragmatic defect or with stitches fixed to the ribs when
closure can be achieved without a patch. Whereas pectus
excavatum and vertebral deformities are associated with
large diaphragmatic defects, obstructive and/or restrictive
pulmonary function anomalies are more often associated
with scoliosis [69, 108].
Some studies show that children with CDH treated with
ECMO may suffer from delayed neurological development
and risk deafness [78]. These effects may be higher in
children born with CDH and treated with ECMO than in
children born without CDH and treated with ECMO [4, 65].
Other studies find that whether or not ECMO is used makes
no difference in the neurological development of children
born with CDH [31, 46, 92]. Because ECMO has been
associated with neurological complications due to the use
of anticoagulant treatment, it is usually reserved for very
sick babies with high pulmonary hypertension and a high
risk of hypoxic and ischemic brain injuries, characteristics
which in themselves entail a prognosis of long-term
morbidity. As for sensorineuronal hearing loss, it is a risk
for babies born with CDH because of the use of ototoxic
medications such as diuretics, muscle relaxants, and anti-
biotics [31]. Prolonged ventilation is also a factor of risk
[112].
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